Chronic Pain in the General Population of Chile

NCT06353100 | Completed DMC

• 1 other identifier: 230602006
• Study Type: observational
• Target: 2,365
• Locations: 1 country
• Sites: 1

Brief Summary

The present study seeks to follow up the cohort of adults representative of Chile's urban population whose levels of chronic pain were evaluated in March 2023 (baseline) as part of the Mental Health Thermometer (MHT) study. The study consists of a 12 month follow-up telephone interview to assess parameters of chronic pain (CP) and subtypes, mental and physical health, lifestyle and adversity and work characteristics. The study objectives are as follows:

1. 1.Estimate the prevalence of CP and subtypes in the general population
2. 2.Explore the association between mental health indicators, perceived work stress and presence of CP in the population.
3. 3.Investigate the impact of CP (functional, occupational and social) among the subset of participants reporting CP
4. 4.Describe the use of management strategies in those who suffer from CP.

Conditions

Chronic Pain; Migraine Disability; Neuropathic Pain; Fibromyalgia; Depression, Anxiety; Self Harm; Insomnia; Loneliness

Keywords

Chronic pain; Depression; Anxiety; Incidence; Prevalence

Outcome Measures

Primary Outcomes (3)

• Chronic pain (past 3 months)

  Participants will be asked "Have you had constant or frequent pain \[most of the day\] during the past 3 months?" and asked to identify the average and maximum intensity of pain in that period using a visual analogue scale (VAS) from 0 to 10. Only participants with an average pain of 4 or more will be classified as having significant chronic pain.

  Baseline and 12-month follow-up

• Depression (2 weeks)

  As measured by the Patient Health Questionnaire (PHQ-9). Total scores on the PHQ-9 range from 0 to 27 and higher scores indicate higher symptoms of depression.

  Baseline and 12-month follow-up

• Anxiety (2 weeks)

  As measured by the General Anxiety Disorder (GAD-7). Total scores on the GAD-7 range from 0 to 21 and higher scores indicate higher symptoms of anxiety.

  Baseline and 12-month follow-up

Secondary Outcomes (6)

• Migraine Disability

  12-month follow-up

• Neuropathic Pain

  Baseline and 12-month follow-up

• Fibromyalgia

  12-month follow-up

• Self harm (2 weeks)

  Baseline and 12-month follow-up

• Insomnia (2 weeks)

  Baseline and 12-month follow-up

Study Arms (4)

Longitudinal analysis group 1 (no pain)

Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 or march 2024

Longitudinal analysis group 2 (incident chronic pain)

Participants (general population residing in urban areas of Chile aged 18 years or more) not reporting chronic pain in march 2023 but reporting chronic pain in march 2024

Longitudinal analysis group 3 (remitted chronic pain)

Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 but not reporting it in march 2024

Longitudinal analysis group 4 (chronic pain at follow up)

Participants (general population residing in urban areas of Chile aged 18 years or more) reporting chronic pain in march 2023 and march 2024

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Community survey in Chile

You may qualify if:

• General population
• Residence in urban areas

Sponsors & Collaborators

• Pontificia Universidad Catolica de Chile: lead
• Chilean Safety Association (ACHS): collaborator

Study Sites (1)

Pontificia Universidad Catolica de Chile

Santiago, RM, 7550139, Chile

Location

MeSH Terms

Conditions

Chronic Pain; Neuralgia; Fibromyalgia; Depression; Anxiety Disorders; Self-Injurious Behavior; Sleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Behavioral Symptoms; Behavior; Mental Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders

Study Officials

• Antonia Errazuriz, PhD

  Pontificia Universidad Catolica de Chile

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 5, 2024
• First Posted: April 8, 2024
• Study Start: January 1, 2023
• Primary Completion: April 30, 2025
• Study Completion: September 25, 2025
• Last Updated: December 12, 2025

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: Upon first manuscript submission
• Access Criteria: For researchers

Locations

CL (1)